A Phase 2 trial of CMP-001 with PD-1 blockade for the treatment of Anti-PD-1 refractory melanoma
Latest Information Update: 24 Sep 2020
At a glance
- Drugs Programmed cell death-1 ligand-1 inhibitors (Primary) ; Vidutolimod (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Checkmate Pharmaceuticals
- 24 Sep 2020 New trial record
- 18 Sep 2020 According to a Checkmate Pharmaceuticals media release, the company is actively engaging with potential clinical sites and remains on track to initiate the trial by late 2020/early 2021.